Evaluation of 18F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amlyoid load in Alzheimer ’s disease

ConclusionsTreatment-related18F-flutemetamol longitudinal changes in AD clinical trials can be quantified using a subcortical white matter reference region without PVC.Clinical trial registration: clinicaltrials.gov NCT01739348.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research